Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.

This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters the company’s small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands their overall proprietary product portfolio. Copernicus’s fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large-scale manufacturing capabilities. Furthermore, Copernicus’s marketed reusable pen injectors are of great value from a sustainability standpoint.

With this acquisition Nemera establishs an operations footprint in Eastern Europe. In order to accompany Copernicus’s solid forecasted growth, they will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.

Marc Hämel, CEO of Nemera said, “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.

“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.

Montagu first partnered with Nemera in its 2014 carve-out from Rexam.  Montagu reinvested in the business in 2019 supporting its ambitious organic and acquisitive growth plans.